Watanabe J, Saito M, Horimoto Y, Nakamoto S, et al. A maintained absolute lymphocyte count predicts the overall survival benefit from
eribulin therapy, including eribulin re-administration, in HER2-negative advanced
breast cancer patients: a single-institutional experience. Breast Cancer Res Treat 2020 Apr 5. pii: 10.1007/s10549-020-05626.
PMID: 32249370